Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience.
Sabrina ChiloiroAntonella GiampietroAmato InfantePier Paolo MattognoLiverana LaurettiAlessandro OliviLaura De MarinisAlfredo PontecorviFrancesco DogliettoAntonio BianchiPublished in: Pituitary (2024)
Our preliminary data suggested that in conventional and multi-drug resistant acromegaly, the combination therapy Pasi-Lar + Peg-V may prevent the worsening of BMD and the occurrence of i-VFs. Prospective and translational studies should further validate these results and ascertain underlying physiopathology mechanisms.
Keyphrases
- drug resistant
- combination therapy
- multidrug resistant
- healthcare
- acinetobacter baumannii
- public health
- risk assessment
- growth hormone
- bone mineral density
- mental health
- drug delivery
- electronic health record
- health information
- big data
- study protocol
- randomized controlled trial
- clinical trial
- case control
- bone loss
- postmenopausal women
- climate change